Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re EpiPen ERISA Litigation (Klein et al v. Prime Therapeutics, LLC et al)
Case Number:
0:17-cv-01884
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Alston & Bird
- Berman Tabacco
- Bradford & Wilson
- Burns Charest
- Dorsey & Whitney
- Edelsberg Law
- Ellis George
- Faegre Drinker
- Keller Rohrback
- Lanier Law Firm
- Lockridge Grindal
- Mayer Brown
- Quinn Emanuel
- Robbins Geller
- Sharp Law LLP
- Spencer Fane
- Steptoe LLP
- Stinson LLP
- Williams & Connolly
- Zimmerman Reed
Companies
- CVS Health Corp.
- Express Scripts Holding Co.
- Medco Health Solutions Inc.
- Optum Inc.
- OptumRx Inc.
- UnitedHealth Group Inc.
Sectors & Industries:
-
August 05, 2020
EpiPen Buyers Lose Bid For Class Status In ERISA Suit
A Minnesota federal judge denied class certification to EpiPen buyers Wednesday in a suit accusing Express Scripts, CVS Health and other pharmacy benefit managers of violating the Employee Retirement Income Security Act by causing plan participants to overpay for the device.
-
December 17, 2019
EpiPen Buyers Seek Class Status In ERISA Suit
A proposed class of EpiPen buyers is asking a Minnesota federal judge for certification in their suit accusing Express Scripts, CVS Health and other pharmacy benefit managers of violating ERISA by causing plan participants to overpay for the drug.
-
October 26, 2018
ERISA Suit Over EpiPen Costs Remains Alive
A Minnesota federal judge on Friday refused to completely toss an Employee Retirement Income Security Act suit accusing Express Scripts Holding Co., CVS Health Corp. and other pharmacy benefit managers of causing large increases to EpiPen's list price, but did find that some claims failed.
-
June 04, 2018
Express Scripts, CVS Want EpiPen Cost ERISA Suit Tossed
Express Scripts Holding Co., CVS Health Corp. and other pharmacy benefit managers urged a Minnesota federal judge Friday to toss a proposed class action alleging that they breached their Employee Retirement Income Security Act duties and caused large increases to EpiPen's list price, arguing that the companies weren't fiduciaries subject to the law.
-
June 05, 2017
Express Scripts, CVS Face ERISA Suit Over EpiPen Costs
Express Scripts, CVS Health and Prime Therapeutics on Friday were drawn into the conflict over how EpiPens became so expensive after a potential class of patients accused the pharmacy benefit managers of violating the Employee Retirement Income Security Act by putting their own interests before those of patients.